Knight James C, Cornelissen Bart
CR-UK/MRC Gray Institute for Radiation Oncology and Biology, University of Oxford Oxford, OX3 7LJ, United Kingdom ; Radiobiology Research Institute, Churchill Hospital Oxford, OX3 7LJ, United Kingdom.
Am J Nucl Med Mol Imaging. 2014 Mar 20;4(2):96-113. eCollection 2014.
Due to their rapid and highly selective nature, bioorthogonal chemistry reactions are attracting a significant amount of recent interest in the radiopharmaceutical community. Over the last few years, reactions of this type have found tremendous utility in the construction of new radiopharmaceuticals and as a method of bioconjugation. Furthermore, reports are beginning to emerge in which these reactions are also being applied in vivo to facilitate a novel pretargeting strategy for the imaging and therapy of cancer. The successful implementation of such an approach could lead to dramatic improvements in image quality, therapeutic index, and reduced radiation dose to non-target organs and tissues. This review will focus on the potential of various bioorthogonal chemistry reactions to be used successfully in such an approach.
由于其快速且高度选择性的特性，生物正交化学反应最近在放射性药物领域引起了极大的关注。在过去几年中，这类反应在新型放射性药物的构建以及作为生物共轭方法方面展现出了巨大的实用性。此外，开始有报道称这些反应也正在体内应用，以促进一种用于癌症成像和治疗的新型预靶向策略。这种方法的成功实施可能会显著提高图像质量、治疗指数，并减少对非靶器官和组织的辐射剂量。本综述将聚焦于各种生物正交化学反应在这种方法中成功应用的潜力。
